QRISK3 Tool Predicts Thrombosis Risk in Essential Thrombocythemia & Polycythemia Vera
QRISK3 Score Shows Promise in predicting Thrombotic Risk in Essential Thrombocythemia and Polycythemia Vera
Table of Contents
Understanding Thrombotic Risk in Myeloproliferative Neoplasms
Essential thrombocythemia (ET) and polycythemia vera (PV) are chronic myeloproliferative neoplasms (MPNs) characterized by an overproduction of blood cells. A notable complication for patients with these conditions is the risk of thrombotic events – the formation of blood clots that can lead to stroke, heart attack, or deep vein thrombosis. Accurately assessing this risk is crucial for guiding treatment decisions, but current methods have limitations. Traditionally,risk stratification relies on clinical and demographic factors,but a new study suggests the QRISK3 risk assessment tool may offer a more effective approach.
QRISK3: A Novel Risk Assessment Tool for ET and PV
The QRISK3 score is a widely used tool in the general population to estimate the 10-year risk of cardiovascular disease. It incorporates various clinical and demographic variables, including age, history of hypertension, atrial fibrillation, severe mental illness, and high body mass index (BMI), providing a thorough evaluation of an individual’s risk profile. Researchers recently investigated whether this tool could be applied to patients with ET and PV to better predict their risk of thrombotic events.
A retrospective study, published in Leukemia, involved 490 patients with ET and 447 patients with PV. Investigators used the QRISK3 assessment to score these patients and then correlated their scores with the occurrence of thrombotic events over a median follow-up period of 85 months for the ET cohort and 95 months for the PV cohort. During this time, 52 thrombotic events were reported in the ET group and 73 in the PV group.
QRISK3 Outperforms Conventional Risk Assessments
The study revealed a strong association between QRISK3 scores and thrombotic risk.Patients identified as high-risk based on conventional assessments also tended to have higher median QRISK3 scores. Specifically, high-risk ET patients had a median QRISK3 score of 4.2, compared to 2.4 in low-risk patients. Similarly, high-risk PV patients scored 8.8, while low-risk patients averaged 2.8 (P < .001). Importantly, the researchers found that using a QRISK3 score above 7.5% was a more effective method for risk stratification than conventional assessments. This cutoff aligns with the threshold used to define high and low risk of thrombotic events in the general population. This suggests a potential for standardized risk assessment across different patient populations.
Cytoreductive Therapy benefits High-Risk Patients Identified by QRISK3
Beyond simply identifying risk, the study explored the impact of intervention. Researchers discovered that patients with QRISK3 scores above 7.5% who received cytoreductive treatment – medication to reduce blood cell production – experienced significantly lower rates of thrombotic events compared to those managed with active surveillance alone.
Among patients with QRISK3 scores at or above 7.5% receiving cytoreductive therapy, 79.7% of ET patients and 86.9% of PV patients remained thrombosis-free. in contrast, only 64.1% of ET patients and 57.1% of PV patients with scores of at least 7.5% who did not receive cytoreductive treatment remained thrombosis-free (P = .018/.034).This highlights the potential benefit of proactive treatment in individuals identified as high-risk by the QRISK3 score.
Implications for Clinical Practice and Future research
The findings suggest that the QRISK3 tool could be a valuable addition to the clinical assessment of patients with ET and PV, not only at diagnosis but also for ongoing, longitudinal risk evaluation.”QRISK3 score appears to be a valid tool that can be applied successfully in PV and ET to help improve thrombotic risk assessment, suggesting the utility of active cytoreductive treatment in high-risk patients,” concluded the study authors, led by Dr. Alessandro Duminuco.
This research opens avenues for further investigation into personalized treatment strategies for MPNs.Utilizing a readily available and validated tool like QRISK3 could lead to more informed decisions regarding cytoreductive therapy, ultimately improving outcomes for patients with ET and PV.
References
- Duminuco A, Vaghela R, Virdee